lilly tirzepatide trial New clinical trial: Zepbound (tirzepatide) helped adults lose an average of 20.2% of their body weight—around 50 lbs—over 72 weeks, outperforming Wegovy's 13.7% (~33 lbs). Credit to: https://www.healthline.com/health-news/zepbound-wegovy-weight-loss Mounjaro measures up to Trulicity

BPC-157 research demonstrates reduced excitotoxicity, enhanced neurotrophic factor expression, and general protective effects on nervous tissue

The cyanide (prussic acid) in cyanocobalamin in supplements is generally not dangerous for the consumer

Many randomized trials show modest average differences under one kilogram in short studies

They started phase three

Short-Term Health Risks That May be Experienced Gastrointestinal Issues The most commonly reported side effects of GLP-1 agonists are gastrointestinal in nature

GIP and GLP-1 receptor agonists slow stomach emptying, which increases aspiration risk during general anesthesiaa complication that can be serious